Brief: Nordic Nanovector Provides Update On Lymrit 37-05 Phase 1 DLBCL Trial

Thor Medical ASA

12/12/2019 06:06

Dec 12 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * NORDIC NANOVECTOR PROVIDES UPDATE ON LYMRIT 37-05 PHASE 1
DLBCL
TRIAL
    * ON THREE COMPLETED COHORTS, NO SAFETY ISSUES WERE
IDENTIFIED
    * EXPECT TO COMPLETE DATA READ-OUT FOR DOSE-ESCALATION PHASE
AND
SUBMIT DATA TO AN INTERNATIONAL CONGRESS IN 1H 2020

Source text for Eikon:  ID:nObiQKMM1a 
Further company coverage:  NANOV.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))